Patents Assigned to Hoffmann-La Roche
-
Publication number: 20240140933Abstract: The present invention relates to compounds of formula (I), wherein R1 to R3, A1 to A3 and n are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: November 20, 2023Publication date: May 2, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Fabian DEY, Dong DING, Xingchun HAN, Chungen LIANG, Hongtao XU, Ge ZOU
-
Publication number: 20240139192Abstract: The present invention is directed to the combination therapy of cancer with a BRAF inhibitor and a MEK inhibitor, as well as uses and pharmaceutical compositions thereof.Type: ApplicationFiled: December 8, 2023Publication date: May 2, 2024Applicants: Hoffmann-La Roche Inc., Chugai Seiyaku Kabushiki KaishaInventors: Jan ECKMANN, Thomas FRIESS, Frank HERTING, Yusuke IDE, Hiroshi TANAKA, Piergiorgio Francesco Tommaso PETTAZZONI, Juergen WICHMANN
-
Patent number: 11970550Abstract: The invention provides anti-variant Fc-region antibodies which specifically bind to an antibody that has the mutation P329G or the mutations P329G/L234A/L235A or the mutations 1253A/H310A/H435A in the Fc-region, and methods of using the same.Type: GrantFiled: December 7, 2020Date of Patent: April 30, 2024Assignee: Hoffmann-La Roche Inc.Inventors: Frank Kowalewsky, Mirko Ritter, Kay-Gunnar Stubenrauch, Uwe Wessels
-
Publication number: 20240132508Abstract: Methods for preparing the Bruton's Tyrosine Kinase (“BTK”) inhibitor compound 2-{3?-hydroxymethyl-1-methyl-5-[5-((S)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4?]bipyridinyl-2?-yl}-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one are provided.Type: ApplicationFiled: November 3, 2023Publication date: April 25, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Stephan BACHMANN, Lukas CHYTIL, Serena Maria FANTASIA, Alec FETTES, Ursula HOFFMANN, Christian Oliver KAPPE, Rene LEBL, Kurt PUENTENER, Paolo TOSATTI, Jason Douglas WILLIAMS
-
Publication number: 20240132574Abstract: Herein is reported a method for the final filtration of concentrated polypeptide solutions comprising the combination of two immediately consecutive filtration steps with a first filter of 3.0 ?m and 0.8 ?m pore size and a second filter of 0.45 ?m and 0.22 ?m pore size.Type: ApplicationFiled: December 20, 2023Publication date: April 25, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Roberto Falkenstein, Klaus Schwendner
-
Publication number: 20240132471Abstract: The invention relates to novel compounds having the general formula Ib wherein R1, R2, R1, R4, R5 and Z are as described herein, composition including the compounds and methods of using the compounds.Type: ApplicationFiled: November 30, 2023Publication date: April 25, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Lea Aurelie BOUCHE, Wolfgang GUBA, Georg JAESCHKE, Stefanie Katharina MESCH, Angélique PATINY-ADAM, Christian SCHNIDER, Sandra STEINER, Andreas Michael TOSSTORFF
-
Publication number: 20240122469Abstract: A virtual reality system for quantifying functional visual capabilities of a user at varying assessment conditions (e.g., varying light, contrast, color conditions), using a head-mountable display. In addition to the high relevance to users with optical conditions, the present embodiments can lead to rapid and simple measurements within the controlled and reproducible testing conditions that virtual reality can offer. The virtual environment system can obtain a selection of a task to be performed. During execution of the task, a virtual environment optical setting (e.g., a modified lighting setting in the virtual environment display) can be dynamically modified. The user can interact with the objects during execution of the task, which can provide an insight into functional visual capabilities of the user. After completion of the task, an output can be generated that quantifies a functional visual capability of the user during execution of the task.Type: ApplicationFiled: December 18, 2023Publication date: April 18, 2024Applicant: HOFFMANN-LA ROCHE INC.Inventors: Geraint Iwan DAVIES, Jonas Franz DORN, Bernhard FEHLMANN, Noémie HURST-FISCHER, Angelos KARATSIDIS, Joerg SPRENGEL
-
Publication number: 20240127957Abstract: Techniques disclosed herein relate to inferring a type of multiple sclerosis and determining whether to output an alert based on codes detected within noisy assessment data corresponding to a subject. The noisy assessment data includes content originating from a care provider that identifies a characteristic of the subject or of a treatment for the subject, and the subject has been diagnosed with multiple sclerosis. A temporal dynamic or distribution is determined based on instances of the code detection, and a modulation is determined based on the temporal dynamic or the distribution. It is determined whether an alert criterion is satisfied based on whether the modulation is above a threshold so as to represent noise or a predicted transition across types of multiple sclerosis. The inferred type of multiple sclerosis is output. When the alert criterion is satisfied, an alert is output as well.Type: ApplicationFiled: November 10, 2023Publication date: April 18, 2024Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC.Inventors: Shemra Rizzo, Kelly Anne Zalocusky, Katherine Anne Belendiuk, Nicole Gidaya Bonine, Yifeng Chia, Laura Gaetano, Ryan William Gan, Jumaah Ingram Goldberg, Xiaoming Jia
-
Patent number: 11958912Abstract: Herein is reported a method for determining the binding interaction with a multimeric antigen of an antibody of the human IgG1 subclass that has at least two binding sites specifically binding to the antigen comprising the steps of 1) determining the binding affinity of the antibody for the multimeric antigen, and 2) incubating a mixture comprising the antibody and a polypeptide that is derived from lysine-gingipain of Porphyromonas gingivalis under conditions and for a time sufficient to cleave the antibody into Fabs and Fc-region, and determining the binding affinity of the Fabs of the antibody for the multimeric, whereby the binding affinity of the antibody to the multimeric antigen to be affinity-driven if the binding affinity determined in both steps are comparable and to be avidity-driven if the binding affinity determined in both steps are different.Type: GrantFiled: October 2, 2020Date of Patent: April 16, 2024Assignee: HOFFMANN-LA ROCHE INC.Inventors: Joerg Moelleken, Michael Molhoj, Christian Gassner, Manuel Endesfelder, Joerg-Thomas Regula
-
Publication number: 20240117029Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.Type: ApplicationFiled: November 14, 2023Publication date: April 11, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Jens FISCHER, Guy GEORGES, Anton JOCHNER, Gregor JORDAN, Hubert KETTENBERGER, Joerg MOELLEKEN, Tilman SCHLOTHAUER, Georg TIEFENTHALER, Valeria RUNZA, Meher MAJETY, Martin SCHAEFER, Maria VIERT, Shu FENG, Wei Shiong Adrian HO, Siok Wan GAN, Runyi Adeline LAM, Michael GERTZ
-
Publication number: 20240116941Abstract: Disclosed are novel solid forms of compound (I), (3-[(8aS)-7-[[(4S)-5-ethoxycarbonyl-4-(3-fluoro-2-methyl-phenyl)-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-2,2-dimethyl-propanoic acid), and pharmaceutical compositions comprising solid forms thereof having characteristics described herein, which can be used as a HBV capsid inhibitor (or HBV Core Protein Allosteric Modifier), or for the treatment or prophylaxis of a viral disease in a patient relating to HBV infection or a disease caused by HBV infection.Type: ApplicationFiled: December 14, 2023Publication date: April 11, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Jing Xiong, Xuemei Wang
-
Publication number: 20240117049Abstract: The invention relates to novel bispecific antigen binding molecules, comprising at least two antigen binding domains capable of specific binding to OX40 and a particular antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.Type: ApplicationFiled: August 29, 2023Publication date: April 11, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Maria AMANN, Juergen Peter BACHL, Alexander BUJOTZEK, Carina CANTRILL, Harald DUERR, Janine FAIGLE, Sabine IMHOF-JUNG, Christian KLEIN, Thomas KRAFT, Estelle MARRER-BERGER, Ekkehard MOESSNER, Laurene POUSSE, Petra RUEGER, Johannes SAM, Roland STAACK, Dietrich TUERCK, Pablo UMANA, Joerg ZIELONKA
-
Publication number: 20240117308Abstract: Herein is reported a method for producing a thymocyte supernatant comprising the steps of co-cultivating thymocytes and mononuclear cells at a cell ratio of at least 0.5:1.2 in the presence of phorbol-12-myristate-13-acetate and Phytohemagglutinin M for up to 60 hours, and separating the co-cultivation medium from the cells and thereby producing the thymocyte supernatant.Type: ApplicationFiled: December 20, 2023Publication date: April 11, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Sonja OFFNER, Markus HORVATH, Ingried SAAM
-
Patent number: 11952586Abstract: Herein is reported a method for the co-cultivation of single deposited B-cells, which can be of any source, with EL-4 B5 feeder cells in a suitable co-cultivation medium. In the herein reported methods the EL-4 B5 cells have been irradiated with a dose of less than 40 Gy, preferably 9.5 Gy or less. Thereby the EL-4 B5 cells have a higher viability and maintain the ability to divide in cultivation at doses less than 6 Gy.Type: GrantFiled: May 29, 2020Date of Patent: April 9, 2024Assignee: Hoffmann-La Roche Inc.Inventors: Sonja Offner, Friederike Jung
-
Patent number: 11951036Abstract: A device for providing a droplet of a liquid stored in an interior of a vial is disclosed that includes a support body and a resilient dome portion mounted to the support body to form a chamber having air, with the dome portion being configured to create an air flow when activated by compression. The support body includes a vial seat, a nozzle, and air flow and transfer conduits. The support body is arranged, when the vial is received by the vial seat, such that the air flow conduit establishes an air connection between the vial interior and the chamber, the transfer conduit establishes a fluid connection between the vial and the nozzle, and, upon activation of the dome portion, the air flow delivers air into the vial that causes liquid to be transferred from the vial to the nozzle through the transfer conduit.Type: GrantFiled: November 2, 2018Date of Patent: April 9, 2024Assignee: HOFFMANN-LA ROCHE INC.Inventors: Maxime Gaillot, Roberta Leah, Declan Reilly, Thomas Thueer, Jack Carroll, James Coop, Edward Sims, Mark Teucher
-
Patent number: 11951073Abstract: A device for transferring a liquid from a first vial to a second vial is disclosed having a dome portion configured to create an air flow when activated by compression and re-expansion, and a support body tightly supporting the dome portion to form a chamber with air therein. The support body includes first and second vial seats, and a transfer conduit. The first and second vial seats are arranged to receive the first and second vials. When the first and second vials are received in the first and second vial seats, the transfer conduit is arranged to establish a fluid connection between the first vial and the second vial. Upon activation of the dome portion, air is delivered into the first vial, thereby creating a pressure rise in the first vial which causes the liquid to transfer from the first vial to the second vial through the transfer conduit.Type: GrantFiled: November 2, 2018Date of Patent: April 9, 2024Assignee: HOFFMANN-LA ROCHE INC.Inventors: Maxime Gaillot, Roberta Leah, Declan Reilly, Thomas Thueer, Jack Carroll, James Coop, Edward Sims, Mark Teucher
-
Patent number: 11952155Abstract: A method of manufacturing a flexible container housing a drug substance is disclosed that includes forming a first compartment from a flexible sheet-like material, filling a liquid into the first compartment, sealing the first compartment, forming a second compartment from the flexible sheet-like material, filling a dry drug formulation into the second compartment, and sealing the second compartment. The method further involves lyophilizing the drug formulation inside a tubular cartridge, filling the second compartment by introducing the tubular cartridge through an opening of the second compartment such that an open end of the tubular cartridge is positioned distant from the opening of the second compartment, providing the drug formulation from the open end of the tubular cartridge into the second compartment, and withdrawing the tubular cartridge from the second compartment. The first and second compartments are separated by a frangible seal which opens when the first compartment is compressed.Type: GrantFiled: November 25, 2019Date of Patent: April 9, 2024Assignee: HOFFMANN-LA ROCHE INC.Inventors: Carmen Lema Martinez, Joerg Luemkemann, Tobias Werk, Thomas Zumstein, Daniel Kullmann
-
Patent number: 11952363Abstract: The present invention relates to compounds of formula (I), wherein R1 to R4 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.Type: GrantFiled: July 22, 2019Date of Patent: April 9, 2024Assignee: Hoffmann-La Roche Inc.Inventors: Fabian Dey, Zongxing Qiu, Wei Zhu, Ge Zou
-
Publication number: 20240108616Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.Type: ApplicationFiled: November 10, 2023Publication date: April 4, 2024Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC., ABBVIE INC.Inventors: Deepak Sampath, Christian Klein, Wayne John Fairbrother, Sari L. Heitner Enschede, Rod A. Humerickhouse, Andrew W. Roberts, John F. Seymour
-
Publication number: 20240109976Abstract: The present invention relates to combination therapies employing anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists, in particular 4-1 BBL trimer containing antigen binding molecules, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.Type: ApplicationFiled: June 13, 2023Publication date: April 4, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Marina Bacac, Claudia Ferrera Koller, Christian Klein, Mario Perro, Johannes Sam, Pablo Umaña, Wei Xu